The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study-Reference-Cited by-同舟云学术

The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study

Published:2022-11 Issue: Volume:37 Page:57-63
ISSN:2405-6308
Container-title:Clinical and Translational Radiation Oncology
language:en
Short-container-title:Clinical and Translational Radiation Oncology

Author:

Takeda Yuichiro,Kusaba Yusaku,Tsukita Yoko,Uemura Yukari,Miyauchi Eisaku,Yamamoto Takaya,Mayahara Hiroshi,Hata Akito,Nakayama Hidetsugu,Tanaka Satoshi,Uchida Junji,Usui Kazuhiro,Toyoda Tatsuya,Tamiya Motohiro,Morimoto Masahiro,Oya Yuko,Kodaira Takeshi,Jingu Keiichi,Sugiura Hisatoshi

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference25 articles.

1. Therapeutic management options for stage III non-small cell lung cancer;Yoon;World J Clin Oncol,2017

2. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2022. Non-Small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. [Accessed December 7, 2021].

3. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer;Murshed;Int J Radiat Oncol Biol Phys,2004

4. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial;Chun;J Clin Oncol,2017

5. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study;BMC Cancer;2023-08-26